CD274 and non-small cell lung carcinoma: Immunotherapy is the standard mode of treatment for advanced NSCLC, and drugs such as PD‐1/PD‐L1 have been approved as first‐line monotherapy or in combination with chemotherapy for advanced NSCLC.